Johnson & Johnson reports psoriasis data and Johnson & Johnson stock gains 1.62 percent

Published on 10/09/2026 at 16:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The study enrolled 684 patients and reached Week 112. Johnson & Johnson stock costs EUR 231.18 versus EUR 227.50, plus 1.62 percent, on October 9, 2026.

Key points in brief

Johnson & Johnson announced two-year ICOTYDE psoriasis data from a 684-participant Phase 3 study on October 9, 2026.
Johnson & Johnson stock was trading at EUR 231.18 at Lang & Schwarz, plus 1.62 percent versus EUR 227.50.
Second-quarter 2026 revenue reached USD 25.31 billion, while adjusted earnings per share rose 4.7 percent year over year.
Johnson & Johnson is scheduled to report third-quarter results on October 13, 2026.

Geometrisches Bauhaus-Poster mit Kreisen, Dreiecken und Schriftzug PHARMA — Bauhaus-Poster mit geometrischen Formen und Schriftzug PHARMA repräsentiert Branche von Johnson & Johnson, ISIN US4781601046, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) was trading at EUR 231.18 at Lang & Schwarz on October 9, 2026 at 4:36 p.m. CEST, plus 1.62 percent versus the prior close of EUR 227.50. On the same date, Johnson & Johnson announced two-year Phase 3 data for ICOTYDE in plaque psoriasis. The 684-participant study reached Week 112, giving the announcement a concrete clinical milestone ahead of the company's October results.

Three milestones shape the pipeline

On July 15, 2026, second-quarter revenue reached USD 25.31 billion and adjusted earnings per share rose 4.7 percent year over year to USD 2.90, according to Fortune. On September 21, 2026, Johnson & Johnson said European approval for ICOTYDE was supported by four Phase 3 studies involving 2,500 patients. On October 9, 2026, the company reported the 684-participant ICONIC-LEAD update, with results extending through Week 112.

What does ICOTYDE add?

The latest study adds durability to the product story rather than a new approval claim. Johnson & Johnson said the data showed sustained skin clearance and patient-reported improvement through Week 112, with 66 adolescent participants included and no new safety signals identified.

That matters because the medicine is positioned as a targeted oral peptide for moderate-to-severe plaque psoriasis. The study design also included 456 ICOTYDE patients and 228 placebo patients, creating a clear numerical base for interpreting the long-term update.

Results arrive October 13

Johnson & Johnson's second-quarter performance provides the financial backdrop. Fortune reported GAAP diluted earnings per share of USD 2.27 for the second quarter, versus USD 2.29 a year earlier, while adjusted diluted earnings per share reached USD 2.90, up 4.7 percent year over year. Management raised its 2026 reported earnings-per-share guidance to USD 11.60-11.75.

According to MarketBeat, the third-quarter report is scheduled for October 13, 2026, before the market opens, with an investor call at 8:30 a.m. ET. The source lists consensus estimates of USD 2.67 earnings per share and USD 25.38 billion in revenue.

Dates for the next catalysts

The next two dated events are October 13, 2026, for the third-quarter results, and December 8, 2026, for the enterprise business review. Chronopin identifies both dates and says the December event is intended to address strategy, growth catalysts and the longer-term outlook.

Stock gains in trading

At EUR 231.18, the Lang & Schwarz quote stood EUR 3.68 above its EUR 227.50 prior close on October 9, 2026. The move leaves the stock below the USD 281.07 52-week high recorded in the primary-market quote data, while the upcoming results provide the next scheduled test of the company's revenue and earnings outlook.

The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.